Study: NCT01986491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid Y
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid Y
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid Y
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid Y
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid Y
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid X
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid X
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid X
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid X
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid X
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid X
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid Y
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid Y
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid Y
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid Y
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid Y
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid Y
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solution
Description: Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solution
Description: Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).